首页 » BT474R NTCC®拉帕替尼耐药的Her2阳性乳腺癌细胞株BT-474 lapatinib-R BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

BT474R NTCC®拉帕替尼耐药的Her2阳性乳腺癌细胞株BT-474 lapatinib-R BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

  • 价  格:¥599850
  • 货  号:NTCC®-BT-474 lapatinib-R
  • 产  地:北京
点击询问我要采购
 竭诚为您服务!
BioVector NTCC典型培养物保藏中心
联系人:Dr.Xu, Biovector NTCC Inc.

电话:400-800-2947 工作QQ:1843439339 (微信同号)

邮件:Biovector@163.com

手机:18901268599

地址:北京

已注册
 

BT-474 lapatinib-R NTCC®拉帕替尼耐药的Her2阳性乳腺癌细胞株-BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心


BT-474 lapatinib-resistant (BT474R) cells are human breast cancer cells that have become resistant to lapatinib, a drug used to treat breast cancer:
  • Resistance mechanism: BT474R cells have increased AXL expression, which is a novel mechanism of resistance to lapatinib.


  • Sensitivity restoration: AXL kinase inhibition by GSK1363089 (foretinib) can restore lapatinib sensitivity in BT474R cells. ER deprivation or blockade can also restore lapatinib sensitivity by down-regulating AXL.


  • Viability: BT474R cells have a two-fold increased viability after 48 hours of lapatinib treatment.


  • Apoptosis: BT474R cells have a significantly decreased apoptosis after treatment with lapatinib.


  • HER2 and HER3 knockdown: BT474 LLR cells are extremely sensitive to HER2 and HER3 knockdown.


  • Lapatinib dosage: A double dosage of lapatinib (2 μM) suppresses BT474 LLR growth by 60%.


Lapatinib is a tablet taken orally to slow down the growth of cancer cells. It is usually taken once a day, at least 1 hour before or 1 hour after a meal.

BT-474 Cells

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

www.biovector.net


您正在向 biovector.net  发送关于产品 BT474R NTCC®拉帕替尼耐药的Her2阳性乳腺癌细胞株BT-474 lapatinib-R BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心 的询问

点击“立即发送”后,我们将在1个工作日内与您取得联系。